Scarica l'app Stockscreener
1.36
2.86%
-0.04
Dopo l'orario di chiusura:
1.37
0.01
+0.74%
Precedente Chiudi:
$1.40
Aprire:
$1.38
Volume 24 ore:
526.61K
Relative Volume:
0.81
Capitalizzazione di mercato:
$85.80M
Reddito:
$139.77M
Utile/perdita netta:
$-97.62M
Rapporto P/E:
-0.8608
EPS:
-1.58
Flusso di cassa netto:
$-61.71M
1 W Prestazione:
-9.93%
1M Prestazione:
-15.00%
6M Prestazione:
-62.12%
1 anno Prestazione:
-67.92%
Intervallo 1D:
$1.30
$1.445
Intervallo di 1 settimana:
$1.30
$1.58
Portata 52W:
$0.9897
$5.77
Macrogenics Inc Stock (MGNX) Company Profile
Nome
Macrogenics Inc
Settore
Industria
Telefono
301-251-5172
Indirizzo
9704 MEDICAL CENTER DRIVE, Rockville, MD
Confronta MGNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.36 | 95.27M | 139.77M | -97.62M | -61.71M | -1.58 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-07 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-31 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-05-10 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Downgrade | Stifel | Buy → Hold |
| 2024-05-10 | Downgrade | TD Cowen | Buy → Hold |
| 2024-04-26 | Iniziato | B. Riley Securities | Buy |
| 2024-04-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-03-04 | Reiterato | BTIG Research | Buy |
| 2024-02-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-11-22 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-11-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Downgrade | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-02-28 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-04 | Iniziato | SMBC Nikko | Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Buy |
| 2021-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-12 | Aggiornamento | Barclays | Underweight → Overweight |
| 2020-12-22 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-03 | Downgrade | Citigroup | Buy → Neutral |
| 2020-06-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Underweight |
| 2019-12-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Ripresa | Guggenheim | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Guggenheim | Neutral |
| 2019-02-07 | Aggiornamento | Citigroup | Sell → Buy |
| 2019-02-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-02-06 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Downgrade | Citigroup | Neutral → Sell |
| 2018-12-10 | Downgrade | Raymond James | Outperform → Underperform |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-05-31 | Iniziato | Evercore ISI | Outperform |
| 2018-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-31 | Iniziato | Raymond James | Outperform |
Mostra tutto
Macrogenics Inc Borsa (MGNX) Ultime notizie
MacroGenics (NASDAQ:MGNX) Upgraded to Hold at Wall Street Zen - Defense World
Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc.(MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
MacroGenics’ SWOT analysis: biotech firm’s stock faces pipeline challenges By Investing.com - Investing.com South Africa
MacroGenics’ SWOT analysis: biotech firm’s stock faces pipeline challenges - Investing.com
Lazard Asset Management LLC Purchases New Position in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Northern Trust Corp Has $1.76 Million Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Millennium Management LLC Sells 671,179 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Q2 Earnings Forecast for MacroGenics Issued By B. Riley - Defense World
MacroGenics Holds Annual Stockholders Meeting on May 21 - TipRanks
B. Riley Issues Pessimistic Forecast for MacroGenics (NASDAQ:MGNX) Stock Price - Defense World
Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies - Yahoo Finance
Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher - simplywall.st
4 Analysts Assess Macrogenics: What You Need To Know - Benzinga
Macrogenics (MGNX) Target Price Reduced by B. Riley Securities | MGNX Stock News - GuruFocus
MacroGenics (MGNX) Sees Target Price Cut Amid Pipeline Focus | MGNX Stock News - GuruFocus
B. Riley Cuts Price Target on MacroGenics to $3 From $5, Keeps Neutral Rating - marketscreener.com
Stifel Nicolaus Cuts MacroGenics (NASDAQ:MGNX) Price Target to $5.00 - Defense World
Stifel Financial Corp Decreases Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Leerink Partnrs Predicts Weaker Earnings for MacroGenics - Defense World
Drug developer stocks fall as companies navigate clinical roadblocks - BioWorld MedTech
Earnings Release: Here's Why Analysts Cut Their MacroGenics, Inc. (NASDAQ:MGNX) Price Target To US$4.50 - Yahoo Finance
MacroGenics Inc. Reports Q1 2025 Financial Results - TipRanks
Dimensional Fund Advisors LP Has $2.33 Million Position in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates - MSN
MGNX: Barclays Lowers Price Target for Macrogenics | MGNX Stock News - GuruFocus
Stifel cuts MacroGenics stock target to $5, maintains Hold rating By Investing.com - Investing.com Canada
MacroGenics (MGNX) Exceeds Revenue Expectations with Strong Pipe - GuruFocus
Macrogenics Inc (MGNX) Q1 2025 Earnings: EPS Loss of $0.65 Beats - GuruFocus
Macrogenics (MGNX) Receives Updated Price Target from Stifel | M - GuruFocus
MacroGenics (MGNX) Price Target Lowered by Stifel | MGNX Stock N - GuruFocus
MacroGenics (MGNX) Price Target Reduced by Barclays | MGNX Stock News - GuruFocus
MacroGenics price target lowered to $3 from $8 at Barclays - TipRanks
MacroGenics Inc earnings matched, revenue fell short of estimates By Investing.com - Investing.com India
MacroGenics: Q1 Earnings Snapshot - Huron Daily Tribune
MacroGenics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results - GlobeNewswire
MacroGenics Inc earnings matched, revenue fell short of estimates - Investing.com
Macrogenics Inc (MGNX) Q1 2025 Earnings: EPS Loss of $0.65 Beats Estimate, Revenue Soars to $13.2 Million, Surpassing Expectations - GuruFocus
MacroGenics reports Q1 EPS (65c), consensus (69c) - TipRanks
Analysts Set MacroGenics, Inc. (NASDAQ:MGNX) Target Price at $7.43 - Defense World
What To Expect From Macrogenics Inc (MGNX) Q1 2025 Earnings - GuruFocus
Wells Fargo & Company MN Increases Stock Position in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
MGNX DEADLINE ALERT: Bernstein Liebhard LLP Reminds MacroGenics, Inc. Investors of Upcoming Deadline - ACCESS Newswire
Class Action Filed Against MacroGenics, Inc. (MGNX)September 24, 2024 Deadline to Join – Contact Levi & Korsinsky - ACCESS Newswire
Barclays PLC Increases Position in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Levi & Korsinsky Announces an Investigation on Behalf of MacroGenics, Inc. (MGNX) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
Macrogenics Inc Azioni (MGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):